CombiMatrix Announces Sale of DNA Micorarray Synthesizer to Nihon Gene Research Laboratory.Business Editors/Health/Medical Writers BIOWIRE2K NEWPORT BEACH, Calif.--(BUSINESS WIRE)--April 7, 2003 Acacia Research Corporation (Nasdaq:ACTG ACTG Acting ACTG AIDS Clinical Trial Group ACTG Actuating/Actuator )(Nasdaq:CBMX) announced today that CombiMatrix's Japanese subsidiary has sold a DNA Microarray Synthesizer synthesizer Machine that electronically generates and modifies sounds, frequently with the use of a digital computer, for use in the composition of electronic music and in live performance. to Nihon Gene Research Laboratory (NGRL NGRL National Germplasm Resources Laboratory (USDA) ). NGRL will supply the Japanese research and drug discovery market with a custom microarray production and analysis service. Under the terms of the agreement, NGRL has purchased a CombiMatrix custom slide bio-chip synthesizer and entered into a multi-year agreement to purchase bio-chips that will be used to provide contract research services in Japan. CombiMatrix and NGRL have also entered into a co-development and research agreement to investigate various aspects of genetic analysis. Dr. Nakagawara, President of NGRL said, "Our customers demand reliable service and high quality results for their research needs. The flexibility and speed of the CombiMatrix system will allow us to continue to deliver those results for virtually any gene from any organism." "The NGRL Laboratories have provided high quality and dependable analysis and research services to pharmaceutical, medical and basic researchers in Japan since 1994. We are excited to offer our custom chip capabilities to the market through NGRL," said Michael Chansler, Director of International Business Development at CombiMatrix. The CombiMatrix Custom Microarray Synthesizer allows pharmaceutical and life science researchers to specify gene targets, design and synthesize custom semiconductor based microarrays. All equipment, software and database technologies can be installed behind the firewall of the customer for privacy of data and speed of experimental design reiteration. About Nihon Gene Research Laboratory The NGRL Inc. provides services for chromosome analysis chromosome analysis Genetics A procedure in which cells–usually of fetal origin are obtained, either in the 1st trimester by chorionic villus biopsy, or later in pregnancy by amniocentesis, and grown in a tissue culture, to detect major chromosome , DNA synthesis, cloning and basic R&D to the medical, agriculture and pharmaceutical researchers in Japan. The services are offered throughout Japan from their head offices in Sendai. About Acacia Research Corporation Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The Acacia Technologies group licenses its DMT See DSL. and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications, from DNA DNA: see nucleic acid. DNA or deoxyribonucleic acid One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. synthesis/diagnostics to immunochemical im·mu·no·chem·is·try n. The chemistry of immunologic phenomena, as of antigen-antibody reactions. im detection. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Acacia Research-Acacia Technologies (Nasdaq:ACTG) and Acacia Research-CombiMatrix (Nasdaq:CBMX) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement under the Private Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. , recent and forthcoming Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. , recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion